ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Beta-blocker (95% CI) f Downgraded by 1 increment due to indirectness as the outcome was reported as a subset of the protocol outcome all-cause hospitalisation g Unable to calculate as zero events in both arms i Absolute risk difference calculated using RevMan software Table 65: Digoxin versus placebo (CKD class 3-5) Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Digoxin (95% CI) All-cause mortality - CKD class 3a/b 2939 VERY LOWb,c due to risk of bias, imprecision Overalla (from 46 fewer to 18 more) All-cause mortality - CKD class 4-5 218 VERY LOWb,c due to risk of bias, imprecision Overalla (from 149 fewer to 105 more) Death or Hospitalisation - CKD class 3a/b 2939 VERY LOWa,e due to risk of bias, indirectness Low estimated (from 21 fewer to 75 fewer) Death or Hospitalisation - CKD class 4-5 218 VERY LOWb,c,e due to risk of bias, indirectness, imprecision Low estimated (from 201 fewer to 28 more) a Data not sufficient to calculate control risk. Overall risk for given for participants with eGFR around 45 or below 34 respectively b Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias c Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 